PT2552966T - Anticorpos contra csf-1r - Google Patents
Anticorpos contra csf-1rInfo
- Publication number
- PT2552966T PT2552966T PT117134163T PT11713416T PT2552966T PT 2552966 T PT2552966 T PT 2552966T PT 117134163 T PT117134163 T PT 117134163T PT 11713416 T PT11713416 T PT 11713416T PT 2552966 T PT2552966 T PT 2552966T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies against
- against csf
- csf
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31989610P | 2010-04-01 | 2010-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2552966T true PT2552966T (pt) | 2017-09-29 |
Family
ID=44010222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT117134163T PT2552966T (pt) | 2010-04-01 | 2011-03-28 | Anticorpos contra csf-1r |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8263079B2 (enExample) |
| EP (2) | EP3156419A1 (enExample) |
| JP (1) | JP5767310B2 (enExample) |
| KR (1) | KR101439719B1 (enExample) |
| CN (1) | CN102834414B (enExample) |
| AR (1) | AR080698A1 (enExample) |
| AU (1) | AU2011232850B2 (enExample) |
| BR (1) | BR112012024564A2 (enExample) |
| CA (1) | CA2795081C (enExample) |
| CY (1) | CY1119324T1 (enExample) |
| DK (1) | DK2552966T3 (enExample) |
| EA (1) | EA021600B1 (enExample) |
| ES (1) | ES2640909T3 (enExample) |
| HR (1) | HRP20171153T1 (enExample) |
| HU (1) | HUE036379T2 (enExample) |
| IL (1) | IL222222A (enExample) |
| JO (1) | JO3291B1 (enExample) |
| LT (1) | LT2552966T (enExample) |
| ME (1) | ME02806B (enExample) |
| MX (1) | MX2012011234A (enExample) |
| NZ (1) | NZ602621A (enExample) |
| PL (1) | PL2552966T3 (enExample) |
| PT (1) | PT2552966T (enExample) |
| RS (1) | RS56219B1 (enExample) |
| SG (1) | SG183829A1 (enExample) |
| SI (1) | SI2552966T1 (enExample) |
| TW (1) | TWI402078B (enExample) |
| UA (1) | UA111818C2 (enExample) |
| WO (1) | WO2011123381A1 (enExample) |
| ZA (1) | ZA201206926B (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218672A (zh) | 2009-12-10 | 2016-01-06 | 霍夫曼-拉罗奇有限公司 | 优先结合人csf1r胞外域4的抗体及其用途 |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| KR20200044999A (ko) | 2010-05-04 | 2020-04-29 | 파이브 프라임 테라퓨틱스, 인크. | Ｃｓｆ1ｒ에 결합하는 항체들 |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| JP6416630B2 (ja) * | 2012-02-06 | 2018-10-31 | ジェネンテック， インコーポレイテッド | Ｃｓｆ１ｒ阻害剤を用いるための組成物及び方法 |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| TWI713436B (zh) | 2012-08-31 | 2020-12-21 | 美商戊瑞治療有限公司 | 用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法 |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| KR102155857B1 (ko) | 2013-12-09 | 2020-09-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 노화 관련 질환들의 치료를 위한 방법 및 조성물 |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| KR102000224B1 (ko) * | 2014-02-03 | 2019-07-16 | 전대연 | 스마트 이메일 관리방법 |
| EA037561B1 (ru) | 2014-06-23 | 2021-04-14 | Файв Прайм Терапьютикс, Инк. | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| PL3212670T3 (pl) | 2014-10-29 | 2021-06-14 | Five Prime Therapeutics, Inc. | Leczenie skojarzone nowotworów |
| MX2017008218A (es) | 2014-12-22 | 2017-10-18 | Five Prime Therapeutics Inc | Anticuerpos anti-csf1r para tratar pvns. |
| HUE053903T2 (hu) | 2015-04-13 | 2021-07-28 | Five Prime Therapeutics Inc | Kombinációs terápia rák ellen |
| EA039951B1 (ru) | 2015-05-27 | 2022-03-31 | Юсб Биофарма Спрл | Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе |
| EA201890020A1 (ru) | 2015-06-15 | 2018-05-31 | Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити | Способы и композиции для лечения ассоциированных со старением состояний |
| JP6621252B2 (ja) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | 治療耐性がんに対する治療耐性低減剤 |
| MX2017016651A (es) * | 2015-06-24 | 2018-05-14 | Hoffmann La Roche | Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias. |
| EP3108897A1 (en) * | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| JP6587756B2 (ja) * | 2015-11-04 | 2019-10-09 | デューク ユニバーシティー | 免疫毒素およびチェックポイント阻害剤の併用療法 |
| WO2017085566A1 (en) * | 2015-11-20 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increase/induction of immune responses |
| US20180291107A1 (en) * | 2015-11-24 | 2018-10-11 | Eli Lilly And Company | Combination therapy for cancer |
| MA44309A (fr) * | 2015-11-25 | 2018-10-03 | Nogra Pharma Ltd | Oligonucléotides antisens il-34 et leurs procédés d'utilisation |
| ES2900302T3 (es) | 2016-04-28 | 2022-03-16 | Alkahest Inc | Fracciones de plasma como terapia para el crecimiento y la progresión del tumor |
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| TW201825519A (zh) | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| EA039316B1 (ru) | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| EP3558360A1 (en) | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| WO2018144334A1 (en) | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| CA3058944A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| US10357513B2 (en) | 2017-04-26 | 2019-07-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| WO2018213665A1 (en) | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| PE20200797A1 (es) | 2017-08-25 | 2020-08-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen especificamente a b7-h4 humana |
| CN111479586A (zh) | 2017-09-13 | 2020-07-31 | 戊瑞治疗有限公司 | 用于胰腺癌的组合抗csf1r和抗pd-1抗体的组合疗法 |
| WO2019113464A1 (en) * | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2019165077A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| GB201803226D0 (en) * | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| TWI853807B (zh) | 2018-03-28 | 2024-09-01 | 美商必治妥美雅史谷比公司 | 介白素-2/介白素-2受體阿法融合蛋白及其使用方法 |
| CA3100766A1 (en) * | 2018-05-23 | 2019-11-28 | Beigene, Ltd. | Anti-ox40 antibodies and methods of use |
| CN108948200B (zh) * | 2018-07-18 | 2019-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及其应用 |
| CN108948201B (zh) * | 2018-07-18 | 2019-05-07 | 博奥信生物技术（南京）有限公司 | 抗人csf-1r单克隆抗体及应用 |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| EP3830123A1 (en) * | 2018-07-27 | 2021-06-09 | Alector LLC | Anti-siglec-5 antibodies and methods of use thereof |
| US20220242957A1 (en) | 2018-09-27 | 2022-08-04 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
| BR112021006743A2 (pt) | 2018-10-26 | 2021-07-13 | Alkahest, Inc. | uso de plasma e frações plasmáticas para melhoria de dor, cicatrização de ferida e recuperação pós-operatória |
| TWI733274B (zh) | 2018-12-13 | 2021-07-11 | 財團法人生物技術開發中心 | 抗人類csf-1r抗體及其用途 |
| ES2984122T3 (es) * | 2019-03-05 | 2024-10-29 | Inserm Institut National De La Santeet De La Rech Medicale | Biomarcadores para carcinoma de células renales |
| WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
| CN113811331A (zh) * | 2019-05-24 | 2021-12-17 | 安立玺荣生医(香港)有限公司 | 抗csf1r抗体、il10融合蛋白及其用途 |
| CN110499295A (zh) * | 2019-09-11 | 2019-11-26 | 宝船生物医药科技(上海)有限公司 | 一种csf-1r报告基因细胞株及其制备方法和应用 |
| EP4034558A1 (en) | 2019-09-26 | 2022-08-03 | Roche Diagnostics GmbH | Anti-csf-1r antibody |
| CA3158125A1 (en) * | 2019-10-17 | 2021-04-22 | National Health Research Institutes | Use of succinate as biomarker in diagnosis and treatment of cancers |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| CN115806626B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用 |
| AU2024274397A1 (en) | 2023-05-17 | 2025-11-13 | Syndax Pharmaceuticals, Inc. | Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| DE68921364T2 (de) | 1988-04-16 | 1995-06-29 | Celltech Ltd | Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA. |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| EP2246363A1 (en) | 2002-11-15 | 2010-11-03 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| HUE028410T2 (en) | 2005-03-08 | 2016-12-28 | Pfizer Prod Inc | Anti-ctla-4 antibody compositions |
| SG10201500328QA (en) * | 2007-08-21 | 2015-03-30 | Amgen Inc | Human c-fms antigen binding proteins |
| WO2009112245A1 (en) * | 2008-03-14 | 2009-09-17 | Transgene S.A. | Antibody against the csf-1 r |
-
2011
- 2011-03-21 AR ARP110100905A patent/AR080698A1/es unknown
- 2011-03-22 JO JOP/2011/0097A patent/JO3291B1/ar active
- 2011-03-25 TW TW100110442A patent/TWI402078B/zh not_active IP Right Cessation
- 2011-03-28 HU HUE11713416A patent/HUE036379T2/hu unknown
- 2011-03-28 RS RS20170817A patent/RS56219B1/sr unknown
- 2011-03-28 EP EP16196811.0A patent/EP3156419A1/en not_active Withdrawn
- 2011-03-28 EP EP11713416.3A patent/EP2552966B1/en active Active
- 2011-03-28 BR BR112012024564A patent/BR112012024564A2/pt not_active Application Discontinuation
- 2011-03-28 JP JP2013502691A patent/JP5767310B2/ja not_active Expired - Fee Related
- 2011-03-28 KR KR1020127025707A patent/KR101439719B1/ko not_active Expired - Fee Related
- 2011-03-28 SG SG2012064135A patent/SG183829A1/en unknown
- 2011-03-28 DK DK11713416.3T patent/DK2552966T3/en active
- 2011-03-28 HR HRP20171153TT patent/HRP20171153T1/hr unknown
- 2011-03-28 CN CN201180017294.3A patent/CN102834414B/zh not_active Expired - Fee Related
- 2011-03-28 US US13/073,004 patent/US8263079B2/en not_active Expired - Fee Related
- 2011-03-28 SI SI201131235T patent/SI2552966T1/sl unknown
- 2011-03-28 WO PCT/US2011/030148 patent/WO2011123381A1/en not_active Ceased
- 2011-03-28 ES ES11713416.3T patent/ES2640909T3/es active Active
- 2011-03-28 PT PT117134163T patent/PT2552966T/pt unknown
- 2011-03-28 LT LTEP11713416.3T patent/LT2552966T/lt unknown
- 2011-03-28 PL PL11713416T patent/PL2552966T3/pl unknown
- 2011-03-28 MX MX2012011234A patent/MX2012011234A/es active IP Right Grant
- 2011-03-28 NZ NZ602621A patent/NZ602621A/en not_active IP Right Cessation
- 2011-03-28 EA EA201270732A patent/EA021600B1/ru not_active IP Right Cessation
- 2011-03-28 AU AU2011232850A patent/AU2011232850B2/en not_active Ceased
- 2011-03-28 ME MEP-2017-174A patent/ME02806B/me unknown
- 2011-03-28 UA UAA201210763A patent/UA111818C2/uk unknown
- 2011-03-28 CA CA2795081A patent/CA2795081C/en not_active Expired - Fee Related
-
2012
- 2012-09-14 ZA ZA2012/06926A patent/ZA201206926B/en unknown
- 2012-09-27 IL IL222222A patent/IL222222A/en not_active IP Right Cessation
-
2017
- 2017-09-07 CY CY20171100949T patent/CY1119324T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL222222A0 (en) | Antibodies against csf-1r | |
| AP4082A (en) | Anti-cd40 antibodies | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| IL220404A (en) | Antiseptic antibodies | |
| ZA201306869B (en) | Antibody against the csf-1r | |
| HUE040213T2 (hu) | Anti-TIM antitest | |
| LT3342786T (lt) | Anti-dll3 antikūnai | |
| PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
| PT2603528T (pt) | Anticorpos glicosilados em fab | |
| GB201020738D0 (en) | Antibodies | |
| ZA201302459B (en) | Antibodies | |
| GB201002238D0 (en) | Antibodies | |
| GB201007957D0 (en) | Antibody | |
| GB201020751D0 (en) | Antibodies | |
| GB201005062D0 (en) | Antibodies | |
| GB201017780D0 (en) | Antibody |